Literature Scan

Literature Scan

New and noteworthy research from the medial literature landscape

Preexisting Cardiovascular Conditions Nearly Double Heart Failure Risk Among Non-Hodgkin Lymphoma Survivors

Patients with non-Hodgkin lymphoma (NHL) that was treated with anthracycline-based chemotherapy have an increased risk of heart failure (HF), and the chances are even...

Combination Antiplatelet Therapy Associated With Higher Mortality After ICH Than Single Antiplatelet Therapy

Antiplatelet therapy (APT) is associated with increased risk of intracerebral hemorrhage (ICH), though data about the association between APT use and mortality risk after...

Post-AHCT Maintenance Therapy With Rituximab Prolongs Survival in MCL

Maintenance therapy with the anti-CD20 monoclonal antibody rituximab after autologous hematopoietic cell transplantation (AHCT) prolonged event-free, progression-free, and overall survival in patients with mantle...

Treating Financial Toxicity: Subsidies Improve Access to Oral Therapies for Medicare Beneficiaries With Myeloma

Low-income subsidies (LIS), which are available to Medicare beneficiaries who earn less than 150 percent of the federal poverty level, alleviate the financial burden...

Real-World Analysis Confirms Rivaroxaban Reduces Risk of VTE and Major Bleeding, Compared With Warfarin

Previously, a series of phase III trials from EINSTEIN investigators determined that the direct oral anticoagulant (DOAC) rivaroxaban is non-inferior to enoxaparin and warfarin...

The Ins and Outs of Inclusion Criteria for Myeloma Clinical Trials

Clinical trial protocols often incorporate strict eligibility criteria to maximize reproducible, results with minimal risk to trial participants. Unfortunately, restricting a trial’s patient population...

Can a Post-AHCT, High-Intensity Exercise Program Improve Quality of Life in Patients With Myeloma?

Patients with myeloma who undergo autologous hematopoietic cell transplantation (AHCT) may experience a decline in health-related quality of life (HRQoL). Although exercise has been...

Luspatercept Shows Activity in Patients With Lower-Risk MDS and Anemia

Erythropoiesis-stimulating agents (ESAs) are a standard treatment for patients with myelodysplastic syndromes (MDS) and anemia; however, only around one-third of patients have an erythroid...

Using a Comorbidity-Based Composite Model to Predict Mortality in Patients With AML

Researchers developed a new composite model incorporating patient- and disease-specific features to predict mortality in patients with acute myeloid leukemia (AML), according to a...

Early Evidence Suggests PD-1 Inhibitors May Be Effective in Relapsed/Refractory Mediastinal Gray-Zone Lymphoma

Mediastinal gray-zone lymphoma, nodular sclerosis classic Hodgkin lymphoma (cHL), and primary mediastinal B-cell lymphoma have overlapping clinical, histologic, and molecular features, including the frequency...
Advertisement

Current Issue

November 2017, Volume 3, Issue 13

This issue features a behind-the-scenes look at the ASH annual meeting, bringing newly approved gene therapies to patients, and more.